SINGLE-AGENT TOPOTECAN IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: A STUDY IN VIET NAM NATIONAL CANCER HOSPITAL

Platinum-based doublet chemotherapy is still supposed as standard regimen in ovarian cancer. However, the rate of relapse or refractory is also very high and vary from 80-85% with stage III-IV ovarian cancer [1]. The prognosis of platinum-resistant ovarian cancer (relapse or refractory within 6 months after initial treatment) has a median survival of 9–12 months and less than 15% respond to subsequent chemotherapy [2]. Thesedays, there are several agents were introduced to control this disease such as Docetaxel, Etoposid, Gemcitabine, Liposomal doxorubicin with overall response rate vary from 12-27% [3] [4] [5]. The objective of this study was to evaluate response and toxicity of 5-day Topotecan chemotherapy in women with primary and secondary platinum-resistant epithelial ovarian cancer.